PPAR- α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia

PPAR Research

Volumn 2015, Issue , 2015, Pages

  Feng, Xiaomeng ^a   Gao, Xia ^a   Jia, Yumei ^a   Zhang, Heng ^a   Pan, Qingrong ^a   Yao, Zhi ^a   Yang, Ning ^a   Liu, Jia ^a   Xu, Yuan ^a   Wang, Guang ^a   Yang, Xinchun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; FENOFIBRATE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IRISIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; IRISIN BLOOD LEVEL; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

EID: 84949293897     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2015/924131     Document Type: Article

References (46)

1. UK Prospective Diabetes Study Group, "Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, " British Medical Journal, vol. 317, no. 7160, pp. 703-713, 1998.
2. H. N. Ginsberg, M. B. Elam, L. C. Lovato et al., "Effects of combination lipid therapy in type 2 diabetes mellitus, " The New England Journal ofMedicine, vol. 362, no. 17, pp. 1563-1574, 2010.
3. J.-C. Fruchart, F. M. Sacks, M. P. Hermans et al., "The residual risk reduction initiative: A call to action to reduce residual vascular risk in dyslipidaemic patients, " Diabetes & Vascular Disease Research, vol. 5, no. 4, pp. 319-335, 2008.
4. C. P. Cannon, E. Braunwald, C. H. McCabe et al., "Intensive versusmoderate lipid lowering with statins after acute coronary syndromes, "The New England Journal of Medicine, vol. 350, no. 15, pp. 1495-1504, 2004.
5. M. Lella and K. Indira, "A comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetesmellitus patients with hyperlipidemia, " Journal of Advanced Pharmaceutical Technology and Research, vol. 4, no. 3, pp. 166-170, 2013.
6. O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, "Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-,-, and-in the adult rat, " Endocrinology, vol. 137, no. 1, pp. 354-366, 1996.
7. F. A. Monsalve, R. D. Pyarasani, F. Delgado-Lopez, and R. Moore-Carrasco, "Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases, " Mediators of Inflammation, vol. 2013, Article ID 549627, 18 pages, 2013.
8. S. J. Robins, D. Collins, J. T. Wittes et al., "Relation of gemfibrozil treatment and lipid levels withmajor coronary events: VA-HIT: A randomized controlled trial, " The Journal of the American Medical Association, vol. 285, no. 12, pp. 1585-1591, 2001.
9. R. Scott, R. O'Brien, G. Fulcher et al., "Effects of fenofibrate treatment on cardiovascular disease risk in 9, 795 individuals with type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, " Diabetes Care, vol. 32, no. 3, pp. 493-498, 2009.
10. R. Belfort, R. Berria, J. Cornell, and K. Cusi, "Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome, " The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 2, pp. 829-836, 2010.
11. G. Wang, L. He, J. Liu et al., "Coronary flow velocity reserve is improved by PPAR-agonist fenofibrate in patients with hypertriglyceridemia, " Cardiovascular Therapeutics, vol. 31, no. 3, pp. 161-167, 2013.
12. J. Liu, C. Lu, F. Li et al., "PPAR-agonist fenofibrate upregulates tetrahydrobiopterin level through increasing the expression of Guanosine 5-triphosphate cyclohydrolase-I in human umbilical vein endothelial cells, " PPAR Research, vol. 2011, Article ID 523520, 8 pages, 2011.
13. P. Boström, J. Wu, M. P. Jedrychowski et al., "A PGC1-alphadependent myokine that drives brown-fat-like development of white fat and thermogenesis, " Nature, vol. 481, no. 7382, pp. 463-468, 2012.
14. L. Xiang, G. Xiang, L. Yue, J. Zhang, and L. Zhao, "Circulating irisin levels are positively associated with endotheliumdependent vasodilation in newly diagnosed type 2 diabetic patients without clinical angiopathy, " Atherosclerosis, vol. 235, no. 2, pp. 328-333, 2014.
15. G. Sesti, F. Andreozzi, T. V. Fiorentino et al., "High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects, " Acta Diabetologica, vol. 51, no. 5, pp. 705-713, 2014.
16. K. N. Aronis, M. Moreno, S. A. Polyzos et al., "Circulating irisin levels and coronary heart disease: Association with future acute coronary syndrome and major adverse cardiovascular events, " International Journal of Obesity, vol. 39, no. 1, pp. 156-161, 2015.
17. S. Aydin, T. Kuloglu, S. Aydin et al., "Irisin: A potentially candidate marker for myocardial infarction, " Peptides, vol. 55, pp. 85-91, 2014.
18. S. Aydin, S. Aydin, M. A. Kobat et al., "Decreased saliva/serum irisin concentrations in the acutemyocardial infarction promising for being a new candidate biomarker for diagnosis of this pathology, " Peptides, vol. 56, pp. 141-145, 2014.
19. J. I. Castillo-Quan, "Fromwhite to brown fat through the PGC-1alpha dependent myokine irisin: implications for diabetes and obesity, " Disease Models and Mechanisms, vol. 5, no. 3, pp. 293-295, 2012.
20. B. K. Pedersen and M. A. Febbraio, "Muscle as an endocrine organ: focus on muscle-derived interleukin-6, " Physiological Reviews, vol. 88, no. 4, pp. 1379-1406, 2008.
21. J.-J. Liu, M. D. S. Wong, W. C. Toy et al., "Lower circulating irisin is associated with type 2 diabetes mellitus, " Journal of Diabetes and Its Complications, vol. 27, no. 4, pp. 365-369, 2013.
22. Y.-K. Choi, M.-K. Kim, K. H. Bae et al., "Serum irisin levels in new-onset type 2 diabetes, " Diabetes Research and Clinical Practice, vol. 100, no. 1, pp. 96-101, 2013.
23. K. H. Park, L. Zaichenko, M. Brinkoetter et al., "Circulating irisin in relation to insulin resistance and the metabolic syndrome, " Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 12, pp. 4899-4907, 2013.
24. M. Li, M. Yang, X. Zhou et al., "Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome, " The Journal of Clinical Endocrinology & Metabolism, vol. 100, no. 4, pp. 1485-1493, 2015.
25. P. A. Boström and J. M. Fernández-Real, "Metabolism: irisin, the metabolic syndrome and follistatin in humans, " Nature Reviews Endocrinology, vol. 10, no. 1, pp. 11-12, 2014.
26. J. Y. Huh, G. Panagiotou, V. Mougios et al., "FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise, " Metabolism: Clinical and Experimental, vol. 61, no. 12, pp. 1725-1738, 2012.
27. N. M. Al-Daghri, K. M. Alkharfy, S. Rahman et al., "Irisin as a predictor of glucose metabolism in children: sexually dimorphic effects, " European Journal of Clinical Investigation, vol. 44, no. 2, pp. 119-124, 2014.
28. G. Panagiotou, L. Mu, B. Na, K. J. Mukamal, and C. S. Mantzoros, "Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk, " Metabolism, vol. 63, no. 10, pp. 1265-1271, 2014.
29. B. P. Neve, J.-C. Fruchart, and B. Staels, "Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis, " Biochemical Pharmacology, vol. 60, no. 8, pp. 1245-1250, 2000.
30. T. L. Rachid, A. Penna-de-Carvalho, I. Bringhenti, M. B. Aguila, C. A. Mandarim-de-Lacerda, and V. Souza-Mello, "Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue fromdiet-inducedmale obese mice, " Molecular and Cellular Endocrinology, vol. 402, pp. 86-94, 2015.
31. E. H. Koh, M.-S. Kim, J.-Y. Park et al., "Peroxisome proliferatoractivated receptor (PPAR)-activation prevents diabetes in OLETF rats: comparison with PPAR-activation, " Diabetes, vol. 52, no. 9, pp. 2331-2337, 2003.
32. C. W. Park, Y. Zhang, X. Zhang et al., "PPAR agonist fenofibrate improves diabetic nephropathy in db/db mic, " Kidney International, vol. 69, no. 9, pp. 1511-1517, 2006.
33. G. M. Keating, "Fenofibrate: A review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus, " American Journal of Cardiovascular Drugs, vol. 11, no. 4, pp. 227-247, 2011.
34. N. Hennuyer, A. Tailleux, G. Torpier et al., "PPAR , but not PPAR , activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1897-1902, 2005.
35. P. Gervois, R. Kleemann, A. Pilon et al., "Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferatoractivated receptor-activator fenofibrate, " The Journal of Biological Chemistry, vol. 279, no. 16, pp. 16154-16160, 2004.
36. J. Kowalski, B. Okopien, A. Madej et al., "Effects of fenofibrate and simvastatin on plasma sICAM-1 andMCP-1 concentrations in patients with hyperlipoproteinemia, " International Journal of Clinical Pharmacology andTherapeutics, vol. 41, no. 6, pp. 241-247, 2003.
37. M. A. Yakubu, R. H. Nsaif, and A. O. Oyekan, "Peroxisome proliferator-activated receptor activation-mediated regulation of endothelin-1 production via nitric oxide and protein kinase C signaling pathways in piglet cerebral microvascular endothelial cell culture, " Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 2, pp. 774-781, 2007.
38. T.-L. Yue, W. Bao, B. M. Jucker et al., "Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injur, " Circulation, vol. 108, no. 19, pp. 2393-2399, 2003.
39. L. Ibarra-Lara, E. Hong, E. Soria-Castro et al., "Clofibrate PPAR activation reduces oxidative stress and improves ultrastructure and ventricular hemodynamics in no-flowmyocardial ischemia, " Journal of Cardiovascular Pharmacology, vol. 60, no. 4, pp. 323-334, 2012.
40. E. Albrecht, F. Norheim, B. Thiede et al., "Irisin-a myth rather than an exercise-inducible myokine, " Scientific Reports, vol. 5, article 8889, 2015.
41. T. Kurdiova, M. Balaz, M. Vician et al., "Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletalmuscle and adipose tissue: In vivo and in vitro studies, " Journal of Physiology, vol. 592, no. 5, pp. 1091-1107, 2014.
42. H.-H. Wang, X.-W. Zhang, W.-K. Chen, Q.-X. Huang, andQ.-Q. Chen, "Relationship between serum irisin levels and urinary albumin excretion in patients with type 2 diabetes, " Journal of Diabetes and its Complications, vol. 29, no. 3, pp. 384-389, 2015.
43. M. Zhang, P. Chen, S. Chen et al., "The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: A preliminary study, " European Review for Medical and Pharmacological Sciences, vol. 18, no. 11, pp. 1567-1572, 2014.
44. C. Moraes, V. O. Leal, S. M. Marinho et al., "Resistance exercise training does not affect plasma irisin levels of hemodialysis patients, " Hormone andMetabolic Research, vol. 45, no. 12, pp. 900-904, 2013.
45. R. R. Kraemer, P. Shockett, N. D. Webb, U. Shah, and V. D. Castracane, "A transient elevated irisin blood concentration in response to prolonged, moderate aerobic exercise in youngmen and women, " Hormone and Metabolic Research, vol. 46, no. 2, pp. 150-154, 2014.
46. M. P. Jedrychowski, C. D. Wrann, J. A. Paulo et al., "Detection and quantitation of circulating human irisin by tandem mass spectrometry, " CellMetabolism, vol. 22, no. 4, pp. 734-740, 2015.